Literature DB >> 33047306

Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.

Conor I MacKay1, Kingsley Wong1, Scott T Demarest2,3, Tim A Benke2,4, Jenny Downs1,5, Helen Leonard1.   

Abstract

Characterized by early-onset seizures, global developmental delay and severe motor deficits, CDKL5 deficiency disorder is caused by pathogenic variants in the cyclin-dependent kinase-like 5 gene. Previous efforts to investigate genotype-phenotype relationships have been limited due to small numbers of recurrent mutations and small cohort sizes. Using data from the International CDKL5 Disorder Database we examined genotype-phenotype relationships for 13 recurrent CDKL5 variants and the previously analyzed historic variant groupings. We have applied the CDKL5 Developmental Score (CDS) and an adapted version of the CDKL5 Clinical Severity Assessment (CCSA), to grade the severity of phenotype and developmental outcomes for 285 individuals with CDKL5 variants. Comparisons of adapted CCSA and CDS between recurrent variants and variant groups were performed using multiple linear regression adjusting for age and sex. Individuals with the missense variant, p.Arg178Trp, had the highest mean adapted CCSA and lowest mean developmental scores. Other variants producing severe phenotypes included p.Arg559* and p.Arg178Gln. Variants producing milder phenotypes included p.Arg134*, p.Arg550*, and p.Glu55Argfs*20. There are observed differences in phenotype severity and developmental outcomes for individuals with different CDKL5 variants. However, the historic variant groupings did not seem to reflect differences in phenotype severity or developmental outcomes as clearly as analyzed by individual variants.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CDKL5; CDKL5 deficiency disorder; developmental outcomes; epilepsy; genotype; neurodevelopment; phenotype

Year:  2020        PMID: 33047306     DOI: 10.1111/cge.13862

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

1.  International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.

Authors:  Sam Amin; Marie Monaghan; Angel Aledo-Serrano; Nadia Bahi-Buisson; Richard F Chin; Angus J Clarke; J Helen Cross; Scott Demarest; Orrin Devinsky; Jenny Downs; Elia M Pestana Knight; Heather Olson; Carol-Anne Partridge; Graham Stuart; Marina Trivisano; Sameer Zuberi; Tim A Benke
Journal:  Front Neurol       Date:  2022-06-20       Impact factor: 4.086

Review 2.  Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.

Authors:  Dylan C Brock; Scott Demarest; Tim A Benke
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

3.  Analysis of X-inactivation status in a Rett syndrome natural history study cohort.

Authors:  Xiaolan Fang; Kameryn M Butler; Fatima Abidi; Jennifer Gass; Arthur Beisang; Timothy Feyma; Robin C Ryther; Shannon Standridge; Peter Heydemann; Mary Jones; Richard Haas; David N Lieberman; Eric D Marsh; Tim A Benke; Steve Skinner; Jeffrey L Neul; Alan K Percy; Michael J Friez; Raymond C Caylor
Journal:  Mol Genet Genomic Med       Date:  2022-03-23       Impact factor: 2.473

4.  Development of an International Database for a Rare Genetic Disorder: The MECP2 Duplication Database (MDBase).

Authors:  Daniel Ta; Jenny Downs; Gareth Baynam; Andrew Wilson; Peter Richmond; Aron Schmidt; Amelia Decker; Helen Leonard
Journal:  Children (Basel)       Date:  2022-07-25

Review 5.  CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.

Authors:  Nicole J Van Bergen; Sean Massey; Anita Quigley; Ben Rollo; Alexander R Harris; Robert M I Kapsa; John Christodoulou
Journal:  Biochem Soc Trans       Date:  2022-08-31       Impact factor: 4.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.